Home › Funds › Versant Venture Management, LLC › JBIO
Versant Venture Management, LLC position in JBIO
JADE BIOSCIENCES INC · Health Care
Versant Venture Management, LLC reported holding 991,783 shares of JBIO (JADE BIOSCIENCES INC) in its Q3 2026 13F filing — a position valued at US$13.9M, representing 12.77% of its reported portfolio and ranking #4 among its reported holdings. Versant Venture Management, LLC has disclosed JBIO holdings in 6 of the last 6 reported quarters, going back to Q2 2025.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Versant Venture Management, LLC's JBIO position evolved
Versant Venture Management, LLC first disclosed a stake in JBIO in Q2 2025 at 1,525,820 shares (US$15.2M). The position peaked in Q4 2025 at 1,525,820 shares, worth US$23.5M. Across 6 filings, Versant Venture Management, LLC increased the stake 0 time(s), trimmed it 1 time(s) and left it unchanged 4 time(s). The most recent filing (Q3 2026) shows 991,783 shares valued at US$13.9M. Notable position changes include a 35% trim in Q2 2026 (shares fell 37% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2025 | 1.53M | $15.24M | New |
| Q3 2025 | 1.53M | $13.17M | Hold |
| Q4 2025 | 1.53M | $23.54M | Hold |
| Q1 2026 | 1.53M | $21.44M | Hold |
| Q2 2026 | 991.78K | $22.04M | Reduce |
| Q3 2026 | 991.78K | $13.93M | Hold |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About JBIO and 13F data
JBIO (JADE BIOSCIENCES INC) is a Health Care company. 94 other funds we track also report a position in JBIO — the largest reported positions include Fairmount Funds Management LLC (US$101.2M), RA CAPITAL MANAGEMENT, L.P. (US$81.6M), Venrock Adviser, LLC (US$71.6M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding JBIO
- Fairmount Funds Management LLC 4.55M sh · $101.18M · Q2 2026
- RA CAPITAL MANAGEMENT, L.P. 3.67M sh · $81.57M · Q2 2026
- Venrock Adviser, LLC 3.22M sh · $71.56M · Q2 2026
- Bellevue Group AG 3.06M sh · $67.95M · Q2 2026
- Paradigm Biocapital Advisors LP 2.86M sh · $63.49M · Q2 2026
- Avidity Partners Management LP 1.70M sh · $37.79M · Q2 2026
- Soleus Capital Management, L.P. 1.55M sh · $34.46M · Q2 2026
- BAKER BROS. ADVISORS LP 1.23M sh · $27.34M · Q2 2026
- Remedium Capital Partners, LLC 1.81M sh · $25.40M · Q3 2026
- Logos Global Management LP 1.12M sh · $25.00M · Q2 2026
- ACORN CAPITAL ADVISORS, LLC 986.76K sh · $21.93M · Q2 2026
- Foresite Capital Management VI LLC 886.67K sh · $19.70M · Q2 2026
More on Versant Venture Management, LLC
FAQ
How long has Versant Venture Management, LLC held JBIO?
Versant Venture Management, LLC has disclosed JBIO holdings in 6 of the last 6 reported quarters, going back to Q2 2025.
What is Versant Venture Management, LLC's current position in JBIO?
As of Q3 2026, Versant Venture Management, LLC holds 991.78K shares of JBIO (JADE BIOSCIENCES INC), valued at $13.93M, representing 12.77% of its reported portfolio and ranking #4.
Has Versant Venture Management, LLC been buying or selling JBIO?
In the latest 13F filing (Q3 2026), Versant Venture Management, LLC held unchanged its position in JBIO. The position peaked in Q4 2025 at 1.53M shares.
Which other funds hold JBIO?
Other major institutional holders of JBIO include Fairmount Funds Management LLC, RA CAPITAL MANAGEMENT, L.P., Venrock Adviser, LLC, among 94 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.